Sonya’s extensive experience in early development includes a focus on translational medicine, leading programmes in gene therapy, biologics, including antisense RNA, and small molecules. She has led successful interactions with health authorities globally, supporting IND/CTA, first-in-class NMEs, and negotiation of a SPA leading to NDA and MAA. Prior to joining Evox, Sonya was most recently at Gyroscope Therapeutics, where she established and led clinical development, translational medicine and clinical genetics. Previously, Sonya has held leadership positions in clinical development as VP Clinical Development at ProQR leading the company’s cystic fibrosis business. In 2012, she held the position of Executive Director Clinical Development, at Relypsa, following a position at Pfizer as Clinical Lead, directing programmes in nephrology, diabetes, metabolism, and cardiovascular disease. She joined industry in 1997, and early in her career combined biopharmaceutical research with a clinical practice.